The FDA granted breakthrough therapy designation to raludotatug deruxtecan (R-DXd) for platinum-resistant ovarian cancer, primary peritoneal, and fallopian tube cancers.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
FDA Grants Breakthrough Status to Raludotatug Deruxtecan in Ovarian Cancer | CURE
Raludotatug Deruxtecan (R-DXd) Drug name
Breakthrough Therapy Designation type
Platinum-Resistant Ovarian, Peritoneal, Fallopian Tube Cancer types treated